Johnson & Johnson Stock Primed for Rally? Premarket Insights for Nov 3, 2025
Earnings & Guidance Lift Hopes Johnson & Johnson’s Q3 report and guidance boost have underpinned recent optimism. Excluding currency effects, total sales rose 6.8% to $23.99B, with key drugs like Darzalex ($3.67B)